This study establishes NCACC as a generalisable framework for high-confidence rare malignant cell identification across heterogeneous spatial transcriptomic cohorts, highlighting the cIgG-JAK-STAT as a therapeutically actionable driver of liver cancer invasion.
Abstract
Background
Liver cancer exhibits profound spatial and cellular heterogeneity, contributing to tumour progression, invasion and therapeutic resistance. Emerging evidence suggests that rare low-abundance malignant cell populations residing within discrete tissue niches influence these processes. However, their reliable detection and identification remain challenging due to the limitations of conventional spatial and single-cell transcriptomic analyses, which often rely on single-sample convergence and a lack of cross-cohort reproducibility.
Objective
To develop a robust framework for identifying rare malignant cell populations across heterogeneous spatial transcriptomic datasets and to characterise their functional role in liver cancer progression.
Design
We developed the Niche Cluster Atlas with Cellular Co-localisation (NCACC), a dual-layer framework integrating spatial organisation with cellular composition to enable cross-sample niche discovery. NCACC was applied to a comprehensive liver cancer transcriptomic atlas to identify rare niche-associated malignant cell populations.
Results
NCACC stratified liver cancer tumour architecture into reproducible multicellular niche modules and enabled a tumour-invasive front-enriched rare cancer-derived IgG (cIgG)+ epithelial cell population. These cells enhanced proliferative and invasive characteristics and were associated with disease progression. Mechanistic analyses identified a STAT1-dependent cIgG-JAK-STAT signalling axis sustaining the invasive-front phenotype and promoting cIgG+ epithelial cell aggressive behaviours. We then combined structure-guided virtual screening with patient-derived organoid validation to identify nordihydroguaiaretic acid and gallic aldehyde as candidate modulators.
Conclusion
Our study establishes NCACC as a generalisable framework for high-confidence rare malignant cell identification across heterogeneous spatial transcriptomic cohorts, highlighting the cIgG-JAK-STAT as a therapeutically actionable driver of liver cancer invasion.
How spatially structured cellular ecosystems, rather than individual cell types, determine therapeutic response and resistance in lung cancer is organized around a single question - and observations that are reproducible across independent cohorts and platforms are explicitly separate from those that remain confined to...
C. Braicu, R. Pîrlog, A. Nutu et al.· Biochimica et biophysica act...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) confers dismal clinical outcomes largely owing to its robust metastatic propensity, among which liver metastasis accounts for the deadliest metastatic phenotype. The core malignant cell populations governing the onset and outgrowth of PDAC hepatic metastasis, as well as their s...
This study uncovered previously unrecognized immunosuppressive cell populations and key immune regulators that advance understanding of CRC immune evasion and highlight potential targets for personalized immunotherapy.
Dominika Miroszewska, Shi-Yang Song, Víctor Urbiola-Salvador et al.· British Journal of Cancer· 0 citations
Understanding of the spatial and molecular features of PNI in PC may help guide personalized treatment choices for PC patients in the future and may help guide personalized treatment choices for PC patients in the future.
P. V. Salachan, L. Raaby, Jacob Fredsøe et al.· Journal of Hematology & Onco...· 0 citations
This study demonstrates that while no single annotation method is universally optimal, multi-method integration enables the identification of robust multi-layer spatial regulatory programs and provides a more reliable framework for interpreting ST data in complex tumor ecosystems.
Mingke Wu, Yi Ting Zhou, Ding-Jie Xu· Frontiers in Bioinformatics· 0 citations
Results demonstrate that CIS exhibits significant intra-patient heterogeneity not captured by single-site profiling, and support multi-region sampling, which could help improve risk stratification, biomarker development, and prediction of response to intravesical therapies.
Tyler D. Myers, A. Salmasi, M. Meagher et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.